Home Cart Sign in  
Chemical Structure| 1538604-68-0 Chemical Structure| 1538604-68-0

Structure of BLU9931
CAS No.: 1538604-68-0

Chemical Structure| 1538604-68-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BLU9931 is an inhibitor of FGFR4 with IC50 of 3 nM and is less potent for FGFR1/2/3 (IC50 > 150 nM).

Synonyms: BLU9931

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BLU9931

CAS No. :1538604-68-0
Formula : C26H22Cl2N4O3
M.W : 509.38
SMILES Code : C=CC(NC1=CC=CC(C)=C1NC2=NC=C3C=C(C4=C(Cl)C(OC)=CC(OC)=C4Cl)C=CC3=N2)=O
Synonyms :
BLU9931
MDL No. :MFCD28900729
InChI Key :TXEBNKKOLVBTFK-UHFFFAOYSA-N
Pubchem ID :72710839

Safety of BLU9931

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of BLU9931

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR3

    FGFR3, IC50:150 nM

  • FGFR4

    FGFR4, IC50:3 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SNU878 cells 10 µM 72 hours Compare cytotoxicity of BLU9931 with dasatinib PMC8017611
Hep3B cells 10 µM 72 hours Compare cytotoxicity of BLU9931 with dasatinib PMC8017611
HUH7 cells 10 µM 72 hours Compare cytotoxicity of BLU9931 with dasatinib PMC8017611
PLC/PRF/5 cells 10 µM 72 hours Compare cytotoxicity of BLU9931 with dasatinib PMC8017611
Hep3B cells 0.1, 1, 3, 10, 30, 100 μM 48 hours Evaluate the inhibitory effect of BLU9931 on Hep3B cell proliferation, showing an IC50 value of 0.9 μM PMC8933034
Huh7 cells 0.1, 1, 3, 10, 30, 100 μM 48 hours Evaluate the inhibitory effect of BLU9931 on Huh7 cell proliferation, showing an IC50 value of 7.1 μM PMC8933034
H6c7 cells 0.1, 1, 3, 10, 30, 100 μM 48 hours Evaluate the cytotoxicity of BLU9931 on H6c7 cells, showing an IC50 value of 13.4 μM PMC8933034
HepG2 cells 100 nM 24 hours To study the effect of BLU9931 on cyclin D1 levels in HepG2 cells, results showed that BLU9931 treatment significantly reduced cyclin D1 levels. PMC8315028
Hep3B cells 100 nM 24 hours To study the effect of BLU9931 on cyclin D1 levels in Hep3B cells, results showed that BLU9931 treatment significantly reduced cyclin D1 levels. PMC8315028
FGF21KD-FL83B cells 100 nM 24 hours To study the effect of BLU9931 on cyclin D1 levels in FGF21KD-FL83B cells, results showed that BLU9931 treatment significantly reduced cyclin D1 levels. PMC8315028
E3LZ10.7 cells 10 μM BLU9931 impairs the proliferation, migration, and invasiveness of PDAC cell lines. PMC10014113
MIA PaCa-2 cells 10 μM BLU9931 impairs the proliferation, migration, and invasiveness of PDAC cell lines. PMC10014113

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Human PDAC xenograft model Oral gavage 300 mg/kg Twice daily for 4 weeks BLU9931 significantly reduced tumor volumes and decreased expression of HMGA1, FGF19, Ki-67, and fibrosis. PMC10014113

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.82mL

1.96mL

0.98mL

19.63mL

3.93mL

1.96mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories